基于决策辅助 (DICTA) 的一般实践中2型糖尿病的数字化,个性化和协作治疗协议-随机对照试验
Sofie Frigaard Kristoffersen1,2, Jeanette Reffstrup Christensen3,4,5, Louise Munk Ramo Jeremiassen3
1Steno Diabetes Center Odense, Odense University Hospital, 5000 Odense, Denmark.
Nutrients
|August 14, 2025
概括
这项研究测试了基于决策援助 (DICTA) 干预的一般实践中2型糖尿病 (T2D) 的数字化,个性化和协作治疗. 迪克塔将电子健康生活方式指导与临床决策支持相结合,以改善T2D管理.
科学领域:
- 初级护理研究初级护理研究
- 数字健康干预措施 数字健康干预措施
- 糖尿病管理 糖尿病管理
背景情况:
- 许多患有2型糖尿病 (T2D) 的人没有获得最佳的护理.
- 数字干预表明生活方式支持的承诺,但缺乏一般实践的整合.
- 缺乏一般实践支持可能会阻碍采用数字干预措施.
研究的目的:
- 评估DICTA干预在初级保健中对T2D管理的有效性.
- 评估一种结合以患者为中心的生活方式指导和临床决策支持 (CDS) 的数字方法.
- 调查整合智能手机应用程序和一般医生 (GPs) 的CDS工具的影响.
主要方法:
- 一项随机对照试验,涉及400名T2D患者,遍及70家丹麦GP诊所.
- 将全科医生诊所的集群随机化,分为干预 (电子健康指导+CDS) 和控制 (常规护理) 组.
- 干预组接受了1年的个性化电子健康生活方式指导和CDS工具访问.
主要成果:
- 主要结局是估计十年心血管风险的一年变化 (SCORE2-糖尿病).
- 心血管风险是使用多个临床和患者报告的因素来计算的.
- 进一步分析将确定干预措施对降低心血管风险的影响.
结论:
- 迪克塔的干预可能会提供一个可扩展的数字化战略,以加强初级保健中的T2D管理.
- 将以患者为中心的生活方式指导与实时临床决策支持相结合,显示出潜在的潜力.
- 这种方法可以改善治疗优化和T2D护理中的患者结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
374
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
374
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Diabetes: Symptoms, Diagnosis, and Complications
692
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
692
Insulin: Dosing Regimen and Adverse Effects
259
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
259


